CEO — Richard Fang: The filing announces the permanent appointment of the Interim CEO, who is a former CEO and current Board Chairman, representing an internal succession rather than a departure.

Entry into a Material Definitive Agreement. On October 20, 2026, Picard Medical, Inc. (the “Company”) entered into a Warrant Amendment and Exchange Agreement (the “Exchange Agreement”) with the placement agent (the “Warrant Holder”) of its private placement closed on December 26, 2025 (the “December 2025 Private Placement”), and such Warrant Holder’s employee designee (“Designee”, together with the Warrant Holder, “Warrant Holders”) as a party by joinder who is bound by the surrender, release…

Unregistered Sales of Equity Securities. The information in

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On September 30, 2026 (the “Issuance Date”), Picard Medical, Inc. (the “Company”) issued three separate unsecured convertible notes (collectively, the “Notes”) to three accredited investors (each, a “Holder” and collectively, the “Holders”) in the aggregate principal amount of $1.0 million. Each Note bears interest at a rate of 3.0% per annum, calculated on the basis of a 360-day…

by reference. Any issuance of shares of Common Stock upon conversion of the Notes, and any issuance of the pre-funded warrants and the shares of Common Stock upon exercise thereof, will be made pursuant to an available exemption from registration under the Securities Act. The Company expects to rely on Section 4(a)(2) of the Securities Act for the issuance of the pre-funded warrants and, to the extent applicable, Section 3(a)(9) of the Securities Act for securities issued upon conversion or e…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 22, 2026, Picard Medical, Inc. (the "Company") received a letter from the NYSE American LLC ("NYSE American") stating that the NYSE American has accepted the Company's plan (the "Compliance Plan") to regain compliance with the NYSE American’s continued listing standards, specifically Sections 1003(a)(i) and (ii) since, as previously disclosed in Current Reports on Form 8-K filed on May…

Director — Dr. Joe Xiao: The filing reports the appointment of a new director to the board and committees, which is a routine governance event and not a departure of an existing executive.

Director — Dr. Joe Xiao: The filing discloses the appointment of a new director to the board and its committees, which is a standard governance event rather than an executive departure.

CEO — Patrick NJ Schnegelsberg: The CEO is stepping down in a planned leadership transition with an immediate interim successor appointed, indicating an orderly succession rather than a sudden loss.

CFO — Bernard Skaggs: The immediate termination of the Chief Financial Officer is a significant negative event indicating a loss of a key senior executive.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 15, 2026, the Company received a written notice (the “May 15 Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to have stockholders’ equity of at least of $2.0…

of Form 8-K, “Results of Operations and Financial Condition.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date of this report, regardless of any general incorporation language in the filing. In a press release dated May 21, 2026, Picard Medical, Inc. (the “Company”) announced…

Entry into a Material Definitive Agreement. On May 5, 2026, Picard Medical, Inc. (the “Company”), agreed to sell to investors, in a registered public offering (the “Offering”) an aggregate of: (i) 16,666,667 shares (the “Offered Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”), or, in lieu thereof for certain Purchasers, pre-funded warrants to purchase up to 16,666,667 shares of Common Stock (the “Pre-Funded Warrants”), (ii) Series A warrants to purchase up to 16…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has repo…

Unregistered Sale of Equity Securities. The information contained above in

Entry into a Material Definitive Agreement. On May 5, 2026, Picard Medical, Inc. (the “Company”) entered into a Warrant Issuance and Exchange Agreement (the “Exchange Agreement”) with the holder (the “Holder”) of certain of the Company’s outstanding warrants to purchase shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). Pursuant to the Exchange Agreement, the Holder agreed to surrender to the Company those certain warrants to purchase Common Stock, dated D…

of Form 8-K, “Results of Operations and Financial Condition.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, whether made before or after the date of this report, regardless of any general incorporation language in the filing. In a press release dated April 22, 2026, Picard Medical, Inc. (the “Company”) announce…

Material Modification to Rights of Security Holders. So long as the Company have any obligation under this Note, the Company shall not, without the Buyer’s written consent, (a) pay, declare or set apart for such payment, any dividend or other distribution (whether in cash, property or other securities) on shares of capital stock other than dividends on shares of Common Stock solely in the form of additional shares of Common Stock or (b) directly or indirectly or through any subsidiary make an…

Entry into a Material Definitive Agreement. On April 7, 2026, Picard Medical, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Quick Capital, LLC, a Wyoming limited liability company (the “Buyer”), an accredited investor, for the issuance and sale of a convertible promissory note in the principal face amount of $555,555.56 (the “Note”) and 80,128 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), as originat…

Creation of a Direct Financial Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained above in

Unregistered Sale of Equity Securities. The information contained above in

Results of Operations and Financial Condition. On March 25, 2026, Picard Medical, Inc. (the “Company”) issued a press release announcing the Company’s financial and operating results for the fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 and incorporated by reference herein. The information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On December 24, 2025, Picard Medical, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with a single institutional investor (the “Buyer”), pursuant to which the Company agreed to issue and sell, in a private placement exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506(b) of Regulation D, promulgated thereunder (the “Priv…

Unregistered Sale of Equity Securities. The information set forth in

Creation of a Direct Financial Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in